Supplementary Table 1 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401923

2023-01-01

Abstract:PDF file - 72KB, Supplementary Table 1. PCR primers and Sources.

What problem does this paper attempt to address?

Supplementary Table 2 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401920

2023-01-01

Abstract:PDF file - 83KB, Supplementary Table 2. Univariate prognostic analyses of recurrence and OS rates for 152 HCC patients after hepatectomy.
Supplementary Table 3 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401917

2023-01-01

Abstract:PDF file - 127KB, Supplementary Table 3. Cox multivariate analysis of contributory factors to TTR and OS among 152 HCC patients after hepatectomy.
Supplementary Figure 1 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401941

2023-01-01

Abstract:PDF file - 122KB, Supplementary Figure 1. (A) Domain structure of SYK(L) and SYK(S). Sequence and cross-species homology of 23 amino acid residues deleted in SYK(S) are shown. (B) Relative position of PCR primers unique for SYK(L) or SYK(S).
Supplementary Figure 2 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401938.v1

2023-01-01

Abstract:PDF file - 154KB, Supplementary Figure 2. Differential subcellular distribution of SYK(L) and SYK(S) in HCC.
Supplementary Figure 5 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401929

2023-01-01

Abstract:PDF file - 88KB, Supplementary Figure 5. Time to recurrence (TTR) and overall survival (OS) curves based on SYK(L) and SYK(S) co-expression.
Supplementary Figure 3 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401935

2023-01-01

Abstract:PDF file - 166KB, Supplementary Figure 3. Effects of suppressed expression of SYK(L) or SYK(S) on cell proliferation and invasion in Huh7 SYK(L)-positive (A), MHCC-97H both SYK(L) and SYK(S)-positive (B), and SMMC7721 cells ectopically expressing SYK(L) (C) or SYK(S) (D).
Supplementary Materials and Methods and Figure Legends from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Jian Hong,Yunfei Yuan,Jianping Wang,Yadi Liao,Ruhai Zou,Chuanlong Zhu,Binkui Li,Yi Liang,Pinzhu Huang,Zongwei Wang,Wenyu Lin,Yixin Zeng,Jia Le Dai,Raymond T. Chung

DOI: https://doi.org/10.1158/0008-5472.22401926

2023-01-01

Abstract:PDF file - 114KB, Supplementary Figure 4. Suppression of MAPK/ERK signaling by SYK(L), but not SYK(S), in HCC cell lines and xenografts.
Prognostic Significance of Full-length SYK Expression in Human Hepatocellular Carcinoma

Jian HONG,Ru-hai ZOU,Long-jun YANG,Bin-kui LI,Pin-zhu HUANG,Yun-fei YUAN

DOI: https://doi.org/10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2011.0049

2011-01-01

Abstract:[Objective] Spleen tyrosine kinase(SYK) has two isoforms,full-length form SYK(L) and short form SYK(S),which has different roles in human malignant tumor.The reports of SYK(L) in HCC are few.This study was to generate SYK(L)-specific antibody,and investigate the correlation between the expression pattern of SYK(L) protein in HCC and clinicopathological characteristics and prognosis.[Methods] SYK(L)-specific antibody was generated by a biotech company.The expression of SYK(L) was detected in 162 cases of HCC tissues and adjacent non-tumor liver tissues by immunohistochemistry.The relationship between the expression statues of SYK(L) and clinicopathological characteristics and prognosis was analyzed.[Results] The specificity of SYK(L)-specific antibody(SYK-23) was well.The positive rate of SYK(L) was significantly lower in HCC tissues [64.8%(105/162)] than that in adjacent non-tumor tissues [98.1%(159/162)](P < 0.001);moreover,SYK(L) expression was significantly associated with the tumor size,tumor differentiation,satellite nodule and vascular invasion(all P < 0.05).After resection of primary HCC,the patients with SYK(L)-positive tumors had a significant longer recurrence-free survival(RFS) and overall survival(OS) than those with SYK(L)-negative tumors.The multivariate cox proportional hazards regression analysis of prognostic factors for RFS and OS showed that the expression of SYK(L) was an independent factor for prognosis of HCC.[Conclusion] Down-regulation of SYK(L) protein expression may be involved in the carcinogenesis and metastasis of HCC,and is a powerful molecular marker to predict the HCC prognosis.
Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183960

2024-01-01

Abstract:Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.
Supplementary Tables S1-S9 from Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients

Tingting Yan,Linlin Lu,Conghua Xie,Jiamei Chen,Xiaojuan Peng,Liehuang Zhu,Ying Wang,Qiang Li,Jing Shi,Fuyuan Zhou,Ming Hu,Zhongqiu Liu

DOI: https://doi.org/10.1158/1535-7163.22503685.v1

2023-01-01

Abstract:The supplementary data contain Supplementary Tables S1 to S9. Supplementary Table S1. Human Liver Donor Details and Tissue Histology Supplementary Table S2. Incubation Conditions for CYP Activity Assays Supplementary Table S3. Analytical Parameters for Activity Assays of CYPs. Supplementary Table S4. Sequences and MRM Transitions of Proteotypic Peptides for Quantifying CYP Enzymes Supplementary Table S5. Oligonucleotide PCR Primers for Human CYP Enzymes and GAPDH Supplementary Table S6. Summary of Enzyme Kinetic Parameters for Seven CYP Activities in Pooled Human Liver Microsomes. Supplementary Table S7. Summary of Seven CYP Enzymes Activities in Tumor Tissues and Pericarcinomatous Tissues of Patients with HCC Supplementary Table S8. Summary of Seven CYPs Protein Expression Levels in Tumor Tissues and Pericarcinomatous Tissues of Patients with HCC Supplementary Table S9. Summary of Seven CYPs mRNA Expression Levels in Tumor Tissues and Pericarcinomatous Tissues of Patients with HCC
Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191539

2024-01-01

Abstract:Supplementary Table S2. Detailed information of human pancreatic tissue array.
Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers

Akram I. Alwithenani,Mohammad A. Althubiti,MohammadA Althubiti,AkramAlwithenani I

DOI: https://doi.org/10.4103/sjmms.sjmms_300_19

2020-01-01

Saudi Journal of Medicine and Medical Sciences

Abstract:BACKGROUND: Spleen tyrosine kinase (SYK) is an important enzyme in the proliferation and differentiation of all hematopoietic tissues. Its role as a cancer driver is well documented in liquid tumors; however, cumulative evidence has suggested an opposite role in other tumor types.OBJECTIVES: To systematically assess the expression of SYK, its prognostic value and epigenetic status in different cancers using bioinformatics tools.METHODS: In this bioinformatics study, Oncomine database and cBioPortal were used to study the SYK gene expression, Kaplan-Meier plotter to study its prognostic value and MethHC to assess the SYK gene methylation in various cancers.RESULTS: From 542 unique analyses of the SYK gene, it was found to be overexpressed in bladder, breast and colon cancers but downregulated in leukemia, lymphoma and myeloma. Compared with normal tissues, breast and brain tumors showed an overexpression of the SYK gene, whereas lymphoma and leukemia had lower expression. The Kaplan-Meier survival analysis revealed that SYK expression in pancreatic, gastric, liver and lung patients were correlated with better overall survival. Using cBioPortal, prostate cancer was found to have the highest SYK gene mutation frequency, and the mean expression was highest in diffuse large B-cell lymphoma, acute myeloid leukemia and thymoma. Using the MethHC database, SYK promoter hypermethylation was found to be significantly higher in breast, renal, liver, lung, pancreatic, prostatic, skin and stomach cancers compared with the normal tissue (P < 0.005).CONCLUSION: The results of this study indicate the potential use of SYK as a diagnostic and therapeutic target for different type of cancers. However, further experimental data are required to validate these results before use of SYK in clinical settings.

English Else
Supplementary Table S2 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Mao Zhang,Yingying Huang,Jiaomeng Pan,Chen Sang,Youpei Lin,Liangqing Dong,Xia Shen,Yingcheng Wu,Guohe Song,Shuyi Ji,Fen Liu,Mengcheng Wang,Yuyan Zheng,Sirui Zhang,Zefeng Wang,Jianke Ren,Daming Gao,Jian Zhou,Jia Fan,Wu Wei,Jian Lin,Qiang Gao

DOI: https://doi.org/10.1158/2159-8290.24249146.v1

2023-01-01

Abstract:Supplementary Table S2. Differential ASEs, primers and sequences information.
Supplementary Table 1 from Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis

Kristin K. Deeb,Aleksandra M. Michalowska,Cheol-yong Yoon,Scott M. Krummey,Mark J. Hoenerhoff,Claudine Kavanaugh,Ming-chung Li,Francesco J. Demayo,Ilona Linnoila,Chu-xia Deng,Eva Y-H.P. Lee,Daniel Medina,Joanna H. Shih,Jeffrey E. Green

DOI: https://doi.org/10.1158/0008-5472.22368596

2023-01-01

Abstract:Supplementary Table 1 from Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis
Comprehensive Analysis of Prognostic Value and Immune Infiltration of Src Family Kinases in Hepatocellular Carcinoma

Dingjin Yao,Yiran Deng,Si Zhang,Limiao Liang,Li Zhang,Shuqiang Weng,She Chen

DOI: https://doi.org/10.31083/j.fbl2805090

IF: 3.1

2023-01-01

Frontiers in Bioscience-Landmark

Abstract:BACKGROUND:Src family kinases (SFKs) belong to the non-receptor protein tyrosine kinase family and are generally dysregulated in a variety of tumors. This study aimed to thoroughly investigate the mutation status, expression level, prognostic value and relationship with immune infiltration of SFKs in hepatocellular carcinoma (HCC).METHODS:TIMER2.0, UALCAN, cBioPortal, Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan-Meier Plotter were used to analyze the differential expression, genetic alteration, prognostic value and immune cell infiltration of SFKs in HCC patients. Furthermore, we used quantitative real-time PCR (qPCR) and western blot (WB) analysis to measure SFKs mRNA and protein expression in matching specimens of normal tissue and HCC. We analyzed the biological effects of FYN in Huh7 cells and subcutaneous xenograft tumor model. We also studied the biological effects of SRC on Huh7 cells.RESULTS:The mRNA expression levels of LYN, SRC and SRM were elevated in HCC tissues, whereas FYN was reduced. Approximately 10% genetic alterations rate of SFKs was observed in HCC. The mRNA levels of BLK, BRK, FRK, FYN, LCK, LYN, SRC, SRM and YES were correlated with clinical cancer stage. Elevated FYN mRNA levels in HCC were positively correlated with overall survival (OS), whereas SRC was negatively correlated with OS. All SFKs members in HCC were significantly associated with at least half of the six immune-infiltrating cells, including B cells, macrophages, dendritic cells, neutrophils, CD4+ T cells and CD8+ T cells. Furthermore, we confirmed that the protein expression level of FYN was decreased in patients with HCC and in a human hepatoma cell line. Overexpression of FYN suppressed Huh7 cell proliferation, migration, invasion, and tumorigenesis in xenograft nude mice. Knockdown of SRC inhibited Huh7 cell proliferation, migration and invasion.CONCLUSIONS:Dysregulated FYN and SRC expression in HCC is associated with poor prognosis and may be used as novel prognostic biomarkers in patients with HCC.
Frequent Epigenetic Inactivation Of Spleen Tyrosine Kinase Gene In Human Hepatocellular Carcinoma

Yunfei Yuan,Jianping Wang,Jinqing Li,Li Wang,Meixiang Li,Zuli Yang,Changqing Zhang,Jia Le Dai

DOI: https://doi.org/10.1158/1078-0432.CCR-06-0921

IF: 13.801

2006-01-01

Clinical Cancer Research

Abstract:Purpose: The aim of present study was to investigate the methylation and expression status of spleen tyrosine kinase (SYK) in human hepatocellular carcinoma (HCC) and to evaluate this information for its ability to predict disease prognosis. E-cadherin and TIMP-3 methylation was also analyzed here as control because both were associated with poor prognosis in some types of tumors.Experimental Design: We analyzed the methylation status of SYK, E-cadherin, and TIMP-3 in 124 cases of HCC and assessed the correlation of such methylations with clinicopathologic variables and prognosis after tumor resection.Results: We found that SYK, E-cadherin, and TIMP-3 genes were methylated in 27%, 27%, and 42% of HCC neoplastic tissues, respectively. The loss of SYK mRNA or Syk protein expression was highly correlated with SYK gene methylation. The patients with methylated SYK in neoplastic tissues had a significantly lower overall survival rate after hepatectomy than those with unmethylated SYK. No significant difference in overall survival rates, however, was found between groups of patients with methylated and unmethylated E-cadherin or TIMP-3. Patients with negative Syk protein expression had a significantly lower overall survival rate than those with positive Syk protein expression. Multivariate analyses indicated that factors affecting overall survival were tumor-node-metastasis stage, Child-Pugh classification, SYK methylation, or Syk protein status.Conclusions: Our results indicate that SYK methylation and loss of Syk expression in HCC neoplastic tissues are independent biomarkers of poor patient outcome and that determination of SYK methylation or Syk expression status may offer guidance for selecting appropriate treatments.
Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis.

X Wang,X Sun,X Du,F Zhou,F Yang,J Xing,G Dong,X Guo

DOI: https://doi.org/10.1016/j.clinre.2016.10.012

IF: 3.189

2016-01-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:BACKGROUND:Thymidylate synthase (TYMS), a key rate-limiting enzyme in the folate metabolism, plays essential roles in the development of several malignancies including hepatocellular carcinoma (HCC). Nonetheless, the association of the single nucleotide polymorphisms (SNPs) in TYMS gene with the prognosis of Chinese HCC patients remains unknown. METHODS:A total of 492 HCC patients who underwent surgery treatment were included in this study. Five functional SNPs (rs2847153, rs2853533, rs502396, rs523230, and rs9967368) in TYMS gene were genotyped using the iPLEX genotyping system. Multivariate Cox proportional hazards regression model and Kaplan-Meier curve were used to analyze the association of SNPs with survival and recurrence of HCC patients. RESULTS:Two SNPs (rs523230 and rs9967368) in TYMS gene were significantly associated with the overall survival of HCC patients. Patients carrying homozygous variant genotype (VV) of rs523230 had significantly decreased risk of death (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.46-1.00; P=0.048) when compared with those carrying homozygous wild-type (WW) or heterozygous (WV) genotypes, while patients carrying WV+VV genotype of rs9967368 had significantly increased risk of death (HR, 1.46; 95% CI, 1.05-2.04; P=0.026) when compared with those carrying WW genotypes. Cumulative effect analysis showed a significant dose-dependent effect of unfavorable SNPs on OS. CONCLUSIONS:Our study for the first time demonstrates the association of SNPs in TYMS gene and clinical outcome of HCC, suggesting that rs523230 and rs9967368 in TYMS gene might be used to predict clinical outcome of Chinese HCC patients.
Supplementary Table 1 from Hepatitis B Virus X Protein Represses Expression of Tumor Suppressor PTPN18 in Hepatocellular Carcinoma

Zhenyu Zhou,Wei Yu,Huoming Li,Juanyi Shi,Shiyu Meng,Yongcong Yan,Ruibin Chen,Haohan Liu,Jie Wang,Jian Sun,Zhiyu Xiao,Jianlong Zhang

DOI: https://doi.org/10.1158/1541-7786.26934529.v1

2024-01-01

Abstract:Patient's clinicopathologic features using in the IHC.
Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

Hongtao Song,Tong Lu,Donghui Han,Jiayu Zhang,Lunbiao Gan,Chao Xu,Shaojie Liu,Peng Li,Keying Zhang,Zhihao Hu,Hongji Li,Yu Li,Xiaolong Zhao,Jingliang Zhang,Nianzeng Xing,Changhong Shi,Weihong Wen,Fa Yang,Weijun Qin

DOI: https://doi.org/10.1158/0008-5472.27837580

2024-01-01

Abstract:Supplementary Table 2: Genotyping Primers and expected band size
The Short-Form of Spleen Tyrosine Kinase Promotes the Invasion and Metastasis of Human Hepatocellular Carcinoma

HONG Jian,TANG Yun-qiang,LIAO Ya-di,WANG Li,HE Lu,YUAN Yun-fei

DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2013.06.039

2013-01-01

Abstract:Objective To investigate the possible effect of the short form of spleen tyrosine kinase [SYK(S)],on the invasion and metastasis of human hepatocellular carcinoma (HCC),and the underlying mechanism.Methods Immunoblotting and real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) were used to examine the expression of SYK(S) in an immortalized normal liver cell line LO2 and seven human HCC cell lines.Two HCC cell lines,SMMC7721 with no SYK(S) expression and MH-CC-97H with high SYK(S) expression,were used to generate stable cell lines by retroviral transduction.In vitro Matrigel invasion assays were performed to explore the effects of SYK(S) on HCC invasion.Both subcutaneous and orthotopic models (n =6) were used for animal studies,and metastatic nodules in the lung were calculated.Endogenous SYK(S) expression was blocked by small interfering RNA (siRNA) in the SYK(S)-positive HCC cell lines.Epithelial-mesenchymal transition (EMT) related markers,E-cadherin and Vimentin were analyzed by using immunoblotting.In addition,the expression of E-cadherin and Vimentin was also detected in xenograft tissues of SMMC7721-SYK(S) by using immunohistochemistry.Results MHCC-97H and MHCC-97L cells expressed relative higher SYK(S) protein and mRNA,which are the most metastatic among all cell lines used in this study.As compared with parental cells,the invasive ability of MHCC-97H and SMMC7721 cells expressing SYK(S) was obviously increased (P ＜0.05).More importantly,SYK (S) expression facilitated lung metastasis in vivo (P ＜ 0.05).Knockdown of SYK (S) expression led to the increased expression of E-eadherin and reduced expression of Vimentin.On the contrary,the decreased expression of E-cadherin and increased expression of Vimentin were detected in the xenograft tumors of SMMC7721-SYK(S) stable cells by using immunohistochemistry,indicating that SYK(S) promoted HCC metastasis via inducing EMT.Conclusion SYK (S) promotes invasion and metastasis of HCC via inducing EMT.

Supplementary Table 1 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Table 2 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Table 3 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Figure 1 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Figure 2 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Figure 5 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Figure 3 from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Supplementary Materials and Methods and Figure Legends from Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma

Prognostic Significance of Full-length SYK Expression in Human Hepatocellular Carcinoma

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Tables S1-S9 from Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers

Supplementary Table S2 from an Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS-Mutant Intrahepatic Cholangiocarcinoma

Supplementary Table 1 from Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis

Comprehensive Analysis of Prognostic Value and Immune Infiltration of Src Family Kinases in Hepatocellular Carcinoma

Frequent Epigenetic Inactivation Of Spleen Tyrosine Kinase Gene In Human Hepatocellular Carcinoma

Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis.

Supplementary Table 1 from Hepatitis B Virus X Protein Represses Expression of Tumor Suppressor PTPN18 in Hepatocellular Carcinoma

Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer

The Short-Form of Spleen Tyrosine Kinase Promotes the Invasion and Metastasis of Human Hepatocellular Carcinoma